

Clinical trials of reteplase

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
Abciximab + reteplase vs primary intervention			
BRAVE (Kastrati) , 2004 n=125/128 follow-up: 30 days	-	symptom duration <12h	
FINESSE (combination-facilitated PCI) , 2008 [NCT00046228] n=828/806 follow-up: 90 days	combination-facilitated PCI with abciximab plus half-dose reteplase versus primary PCI (abciximab administered immediately before the procedure)	patients with acute ST-segment elevation myocardial infarction; symptom duration <6h	Parallel groups open
reteplase vs accelerated t-PA			
GUSTO III , 1997 n=10138/4921 follow-up: 30 days	reteplase, in two bolus doses or 10 MU each given 30 minutes apart versus alteplase, up to 100 mg infused over a period of 90 minutes	patients within 6 hours after the onset of symptoms with ST-segment elevation or bundle-branch block	Parallel groups open 20 countries
RAPID-2 , 1996 n=169/155 follow-up: 35 days	10 plus 10 megaunits double bolus of reteplase versus front-loaded alteplase	patients with acute myocardial infarction within 12h from onset of ischemic chest pain	Parallel groups open USA, Germany
reteplase vs streptokinase			
INJECT , 1995 n=3004/3006 follow-up: 6 mo	Reteplase 2 bolus de 10 MU 30 min d'intervalle versus Streptokinase 1.5 MU en IV en 60 min	patients with symptoms and electrocardiographic criteria consistent with acute myocardial infarction within 12 h from onset of symptoms	Parallel groups double blind Europe

More details and results :

- myocardial revascularization for acute myocardial infarction in facilitated PCI at <http://www.trialresultscenter.org/go-Q90>
- myocardial revascularization for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q129>
- fibrinolysis for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q260>

References

BRAVE (Kastrati), 2004:

Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schmig A Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004;291:947-54 [[14982910](#)]

FINESSE (combination-facilitated PCI), 2008:

Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neum Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 May 22;358:2205-17 [[18499565](#)]

GUSTO III, 1997:

A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997 Oct 16;337:1118-23 [[9340503](#)]

A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997;337:1118-23 [[9340503](#)]

RAPID-2, 1996:

Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996;94:891-8 [[8790022](#)]

INJECT, 1995:

Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics Lancet 1995;346:329-36 [[7623530](#)]

Entry terms: reteplase, Retavase, Centocor brand of reteplase, Biovail brand of reteplase, Rapilysin, Roche brand of reteplase, , abciximab